Aura Biosciences, Inc. Interest Receivable
Aura Biosciences, Inc. (AURA) had Interest Receivable of $1.76 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2026-08-11
- 2026-06-30: Interest Receivable $1.76M.
- 2025-12-31: Interest Receivable $515.00K.
| Period end | Interest Receivable |
|---|---|
| 2026-06-30 | $1.76M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $515.00K 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |